Perioperative Inflammation and Cyclooxygenase 2 (COX-2)

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Surgery initiates a complex cascade of events involving the release of chemical compounds from nerve endings and damaged tissue which leads to an inflammatory and pain response. The purpose of this investigation is to measure various chemical mediators in the blood and cerebrospinal fluid, and to test the hypothesis that they will be decreased in patients treated with a COX-2 inhibitor.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborator: Pfizer
• Treatments: Valdecoxib

Criteria

Inclusion Criteria:

• Patients undergoing surgery requiring lumbar drain placement

Exclusion Criteria:

• Contraindication to COX-2 inhibitor (renal or hepatic insufficiency)

• Known adverse reaction to nonsteroidal anti-inflammatory drugs (NSAIDs)

• Use of NSAID or COX-2 within 7 days prior to surgery